Equities research analysts predict that Radius Health Inc (NASDAQ:RDUS) will post sales of $40.78 million for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Radius Health’s earnings, with estimates ranging from $37.59 million to $43.00 million. Radius Health posted sales of $22.63 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 80.2%. The business is expected to issue its next earnings results after the market closes on Wednesday, August 7th.
On average, analysts expect that Radius Health will report full year sales of $171.00 million for the current year, with estimates ranging from $167.05 million to $176.51 million. For the next fiscal year, analysts expect that the company will post sales of $235.55 million, with estimates ranging from $205.71 million to $256.03 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Radius Health.
Radius Health (NASDAQ:RDUS) last announced its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.94) EPS for the quarter, topping the consensus estimate of ($0.95) by $0.01. The company had revenue of $29.84 million during the quarter, compared to the consensus estimate of $35.35 million. Radius Health had a negative net margin of 176.84% and a negative return on equity of 233.12%. The company’s quarterly revenue was up 105.1% on a year-over-year basis. During the same quarter last year, the firm posted ($1.11) EPS.
In related news, VP Joseph Francis Kelly acquired 2,500 shares of the company’s stock in a transaction on Friday, June 7th. The shares were acquired at an average cost of $21.81 per share, for a total transaction of $54,525.00. Following the purchase, the vice president now owns 7,500 shares in the company, valued at $163,575. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Anthony Rosenberg sold 1,584 shares of the firm’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $24.60, for a total value of $38,966.40. Following the transaction, the director now owns 8,716 shares in the company, valued at $214,413.60. The disclosure for this sale can be found here. 4.00% of the stock is currently owned by company insiders.
A number of large investors have recently modified their holdings of the business. California Public Employees Retirement System increased its stake in shares of Radius Health by 25.3% during the 4th quarter. California Public Employees Retirement System now owns 73,700 shares of the biopharmaceutical company’s stock worth $1,215,000 after purchasing an additional 14,900 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Radius Health by 8.6% during the 4th quarter. Geode Capital Management LLC now owns 457,063 shares of the biopharmaceutical company’s stock worth $7,536,000 after purchasing an additional 36,093 shares during the last quarter. Two Sigma Investments LP acquired a new position in shares of Radius Health during the 4th quarter worth $981,000. Paloma Partners Management Co acquired a new position in shares of Radius Health during the 4th quarter worth $218,000. Finally, Metropolitan Life Insurance Co. NY increased its stake in shares of Radius Health by 395.0% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 13,549 shares of the biopharmaceutical company’s stock worth $223,000 after purchasing an additional 10,812 shares during the last quarter.
Shares of RDUS stock traded down $1.17 during trading hours on Friday, hitting $20.32. 400,564 shares of the company were exchanged, compared to its average volume of 334,931. The stock has a market capitalization of $989.46 million, a price-to-earnings ratio of -4.16 and a beta of 0.95. Radius Health has a fifty-two week low of $12.81 and a fifty-two week high of $25.40. The company has a debt-to-equity ratio of 6.75, a quick ratio of 5.04 and a current ratio of 5.16. The company’s 50 day simple moving average is $23.01.
Radius Health Company Profile
Radius Health, Inc, a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer.
Featured Article: What is a Real Estate Investment Trust (REIT)?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.